Esperion Therapeutics (ESPR) Shareholder Meditor Group LTD Has Lifted Its Stake by $86.45 Million as Stock Value Rose; Riverpoint Capital Management Lowered Amazon Com (AMZN) Position by $13.02 Million as Market Value Rose

February 15, 2018 - By Marie Mckinney

Riverpoint Capital Management Llc decreased its stake in Amazon Com Inc (AMZN) by 90.23% based on its latest 2017Q3 regulatory filing with the SEC. Riverpoint Capital Management Llc sold 13,548 shares as the company’s stock rose 13.58% with the market. The institutional investor held 1,467 shares of the consumer services company at the end of 2017Q3, valued at $1.41 million, down from 15,015 at the end of the previous reported quarter. Riverpoint Capital Management Llc who had been investing in Amazon Com Inc for a number of months, seems to be less bullish one the $707.09B market cap company. The stock increased 0.66% or $9.56 during the last trading session, reaching $1460.61. About 3.33M shares traded. Amazon.com, Inc. (NASDAQ:AMZN) has risen 37.41% since February 15, 2017 and is uptrending. It has outperformed by 20.71% the S&P500.

Meditor Group Ltd increased its stake in Esperion Therapeutics Inc (ESPR) by 305.47% based on its latest 2017Q3 regulatory filing with the SEC. Meditor Group Ltd bought 1.73 million shares as the company’s stock rose 33.24% with the market. The institutional investor held 2.29M shares of the health care company at the end of 2017Q3, valued at $115.02 million, up from 566,000 at the end of the previous reported quarter. Meditor Group Ltd who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.93 billion market cap company. The stock decreased 0.36% or $0.268 during the last trading session, reaching $73.492. About 161,456 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 15, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Monday, June 26 by Stifel Nicolaus. The stock has “Buy” rating by Bank of America on Friday, January 5. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Wednesday, June 29 report. Needham maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Monday, March 20. Needham has “Strong Buy” rating and $58 target. On Thursday, February 25 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Sell” rating by Chardan Capital Markets given on Friday, August 7. The firm has “Buy” rating given on Monday, August 10 by Needham. The firm earned “Buy” rating on Monday, October 26 by WallachBeth Capital. As per Thursday, June 30, the company rating was maintained by Needham. The rating was downgraded by Barclays Capital to “Equal-Weight” on Wednesday, June 29.

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It is positive, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Eam Invsts Llc holds 0.62% or 92,899 shares in its portfolio. Bailard holds 0.24% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 63,300 shares. Quantbot Lp has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Manufacturers Life Insur Communications The holds 13,095 shares. Citadel Limited Company stated it has 58,332 shares. Gsa Prtnrs Llp reported 0.03% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Stifel Financial Corporation holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 9,092 shares. Nationwide Fund holds 22,952 shares. Bancorp Of Montreal Can reported 1,596 shares. Fincl Bank Of America De reported 34,781 shares. Us National Bank De owns 11,051 shares. Goldman Sachs Group holds 0% or 259,096 shares in its portfolio. Renaissance Ltd Liability Com holds 14,500 shares. Next Finance invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Citigroup Inc holds 0% or 28,552 shares.

Meditor Group Ltd, which manages about $658.73 million US Long portfolio, decreased its stake in Exelixis Inc (NASDAQ:EXEL) by 2.81 million shares to 17.42 million shares, valued at $422.01 million in 2017Q3, according to the filing.

Among 53 analysts covering Amazon.com (NASDAQ:AMZN), 50 have Buy rating, 0 Sell and 3 Hold. Therefore 94% are positive. Amazon.com had 273 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained the shares of AMZN in report on Friday, February 2 with “Buy” rating. As per Wednesday, August 26, the company rating was upgraded by Evercore. The rating was initiated by William Blair with “Outperform” on Friday, June 10. The firm has “Buy” rating given on Friday, October 27 by Piper Jaffray. Oppenheimer maintained Amazon.com, Inc. (NASDAQ:AMZN) on Friday, October 27 with “Outperform” rating. The rating was maintained by Benchmark with “Buy” on Friday, January 29. Maxim Group maintained the shares of AMZN in report on Wednesday, September 28 with “Buy” rating. BMO Capital Markets maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Tuesday, January 16. BMO Capital Markets has “Buy” rating and $1600.0 target. The firm has “Buy” rating given on Thursday, December 1 by Canaccord Genuity. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned “Outperform” rating by Macquarie Research on Tuesday, December 22.

Since August 15, 2017, it had 0 insider purchases, and 2 selling transactions for $5.92 million activity. WILKE JEFFREY A sold $3.25M worth of stock. Olsavsky Brian T sold $2.31 million worth of stock. Jassy Andrew R sold $1.96 million worth of stock or 1,985 shares. $536,666 worth of Amazon.com, Inc. (NASDAQ:AMZN) was sold by Reynolds Shelley on Tuesday, August 15. 2,077 shares valued at $2.05M were sold by Blackburn Jeffrey M on Tuesday, August 15.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>